victrelis
merck sharp dohme ltd - boceprevir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - victrelis er indiceret til behandling af kronisk hepatitis-c (chc) genotype-1 infektion, kombineret med peginterferon alfa og ribavirin hos voksne patienter med kompenseret leversygdom som tidligere ubehandlet, eller der ikke har foregående terapi.
quetiapin "actavis" 200 mg depottabletter
actavis group ptc ehf. - quetiapin fumarat - depottabletter - 200 mg
quetiapin "actavis" 300 mg depottabletter
actavis group ptc ehf. - quetiapin fumarat - depottabletter - 300 mg
quetiapin "actavis" 400 mg depottabletter
actavis group ptc ehf. - quetiapin fumarat - depottabletter - 400 mg
quetiapin "actavis" 50 mg depottabletter
actavis group ptc ehf. - quetiapin fumarat - depottabletter - 50 mg
cuadro nt emulsionskoncentrat
fmc agricultural solutions a/s (tidligere: cheminova a/s) - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 250 g/l trinexapac-ethyl ; (~ 222 g/l trinexapac)
orius max 200 ew olie i vand emulsion
nufarm deutschland gmbh - tebuconazol - olie i vand emulsion - 200 g/l tebuconazol
optimus max flydende middel
nufarm deutschland gmbh - trinexapac-ethyl, trinexapac - flydende middel - 175 g/l trinexapac-ethyl ; (~ 156 g/l trinexapac
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunoglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se afsnit 4. 4 og 5.